Consensus Molecular Subtypes Inform HIPEC Agent Selection in Colorectal Cancer Peritoneal Metastases

Key Points

• Patients with colorectal cancer peritoneal metastases showed better outcomes with HIPEC tailored to molecular subtypes.
• In this study, treatment selection based on molecular subtypes improved therapeutic effectiveness, as indicated by response rates.
• Assessment using molecular subtype classification highlighted significant variations in chemotherapy agent efficacy.
• Tailored HIPEC approaches may enable more effective treatments, although further research is needed for broader applications.